Exelixis | EXEL - Ação





Ação Alterar Data
Acadia Pharmaceuticals USD 31.57M 3.1M 2026-03
Agios Pharmaceuticals USD 35.09M 2.17M 2026-03
Akebia Therapeutics USD 13M 2.61M 2026-03
Amgen USD 6.19B 39M 2026-03
AstraZeneca USD 6.57B 13M 2026-03
Bayer EUR 12.34B 3M 2025-12
BioMarin Pharmaceutical USD 1.27B 25.66M 2026-03
Bristol-Myers Squibb USD 2.76B 66M 2026-03
Eisai JPY 236.46B 9.14B 2025-09
Eli Lilly USD 14.53B 785M 2026-03
Esperion Therapeutics USD 104.21M 915K 2026-03
Exelixis USD 26.6M 4.92M 2026-03
Genmab DKK 13M 1000K 2025-06
Glaxosmithkline GBP 6.16B 39M 2026-03
Incyte USD 115.62M 14.56M 2026-03
Ionis Pharmaceuticals USD 5.56M 4.49M 2026-03
MacroGenics USD 9.5M 1.59M 2026-03
Merck USD 6.48B 179M 2026-03
Moderna USD 146M 7M 2026-03
Nektar Therapeutics USD 14.46M 1.78M 2024-06
Neurocrine Biosciences USD 64.5M 4.5M 2026-03
Novartis USD 6.29B 17M 2026-03
Pfizer USD 10.67B 13M 2026-03
Puma Biotechnology USD 9.48M 885K 2025-09
Sanofi EUR 23.5B 812M 2026-03
Takeda JPY 1.41T 107.71B 2025-12
Ultragenyx Pharmaceutical USD 55M 3M 2026-03